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Cholangiocarcinoma is the second most common primary liver
cancer and responds poorly to existing therapies. Intrahepatic
cholangiocarcinoma (ICC) likely originates from the biliary tree and
develops within the hepatic parenchyma. We have generated
a ﬂexible orthotopic allograft mouse model of ICC that incorpo-
rates common genetic alterations identiﬁed in human ICC and
histologically resembles the human disease. We examined the
utility of this model to validate driver alterations in ICC and tested
their suitability as therapeutic targets. Speciﬁcally, we showed
that the fused-in-glioblastoma-c-ros-oncogene1 (FIG–ROS1(S); FIG–
ROS) fusion gene dramatically accelerates ICC development and that
its inactivation in established tumors has a potent antitumor effect.
Our studies establish a versatile model of ICC that will be a useful
preclinical tool and validate ROS1 fusions as potent oncoproteins
and therapeutic targets in ICC and potentially other tumor types.
Cholangiocarcinoma, the second most common primary livercancer, has a dismal prognosis due to its poor responsiveness
to existing therapies. It represents 10–25% of primary liver
cancers worldwide (1), but is more frequent in Asia, due to a
higher prevalence of risk factors such as parasitic infections, bili-
ary-duct cysts, hepatolithiasis, and primary sclerosing cholangitis
(2). Intrahepatic cholangiocarcinoma (ICC) develops within the
liver parenchyma, shows markers of cholangiocyte differentia-
tion, including positivity for cytokeratin 19, and leads to abun-
dant stromal desmoplasia. Whereas surgical resection can be
curative, most patients are not eligible for this procedure due to
advanced disease, and no effective systemic therapy has been
developed to date (3, 4).
Sequencing efforts are beginning to generate in-depth in-
formation about the somatic alterations that occur in cholangio-
carcinoma. Among the most frequently mutated genes are the
tumor suppressor tumor protein p53 (TP53) (37–44%) (5, 6) and
the kirsten rat sarcoma viral oncogene homolog (KRAS) (17–54%)
(6–8), although mutations inMLL3 and SMAD4 are also common
(15% and 17% of cases, respectively) (6). Despite their high mu-
tational frequency, none of these signature genes is amenable to
targeted therapy.
Recently, the mutational spectrum of cholangiocarcinoma has
been extended by the identiﬁcation of ROS1 fusions in nearly
9% of cholangiocarcinoma patients (9). Oncogenic fusion kina-
ses involving the orphan receptor tyrosine kinase ROS1 have
been previously reported at low frequency in lung adenocarci-
noma and glioblastoma and result from chromosomal rear-
rangements that lead to constitutive activation of the ROS1
kinase activity. Consequently, ROS1 presents a potential drug
target for a subset of patients with ICC.
Mouse models have proven a powerful tool for understanding
the relationship between cancer genetics and tumor behavior, but
only a few genetically engineered mouse models (GEMMs) of ICC
exist and many display a mixed ICC/hepatocellular carcinoma
(HCC) histology (10–13). A histopathologically accurate ICC
model has been produced by liver-speciﬁc expression of endog-
enous KrasG12D mutant in combination with Tp53 tumor sup-
pressor gene deletion (14). Still, as with other multiallelic
GEMMs, this model requires time-consuming and expensive
breeding strategies to integrate further genetic changes. More-
over, because the conditional alleles cause the alteration to be
present throughout the entire organ, the majority of GEMMs do
not recapitulate the human microenvironment where cancer cells
and normal cells are both present and interact. Faster and more
ﬂexible in vivo models would greatly facilitate the functional
characterization of candidate driver alterations and therapeutic
targets, as well as produce tractable preclinical models for testing
novel therapies.
Our laboratory has previously established an orthotopic al-
lograft mouse model for hepatocellular carcinoma that is based
on the genetic manipulation of liver progenitor cells followed
by the orthotopic transplantation into recipient mice (15, 16).
This model enabled us to rapidly study genetic interactions
during tumorigenesis as well as to identify and functionally
validate tumor suppressor genes and oncogenes. Here we de-
scribe the development of a similar model for ICC that allows
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us to rapidly interrogate biologically relevant aspects of this
disease. We use this system to functionally validate FIG–ROS
as a potent oncoprotein in ICC and document its requirement
for tumor maintenance, thus conﬁrming its potential as a ther-
apeutic target.
Results
Differential Effects of c-Myc and Kras on Tumors Initiated from Liver
Progenitor Cells. Our previous progenitor-cell–based mouse model
of liver cancer involved the isolation and the retroviral trans-
duction of E-cadherin positive fetal liver cells from p53−/− embryos
with different oncogenes, followed by transplantation of the ge-
netically modiﬁed cell populations into recipient mice. In an at-
tempt to improve this model, we used a strategy to incorporate
conditional mutant alleles exclusively in the hepatic parenchymal
cells. Speciﬁcally, we generated mice harboring an Albumin-Cre
(Alb-Cre) transgene together with two different conditional mutant
p53 alleles (p53lox and p53lslR172H, designated p53lslR172H/lox) (17,
18) (Fig. 1A). As Alb-Cre is a liver-speciﬁc Cre-recombinase
expressed in bipotent liver progenitor cells and adult hepatocytes
(19–21), its expression in the p53lslR172H/lox background produces
liver-speciﬁc expression of a mutant p53 and deletion of the other
allele, which is a typical conﬁguration occurring in human tumors.
Initially, to test whether oncogenes known to cooperate with
p53 mutations would produce liver carcinomas in this model, we
transduced fetal liver cells isolated from Alb-Cre; p53lslR172H/lox
embryos (subsequently referred to as AP cells) with retroviral
vectors coexpressing green ﬂuorescent protein (GFP) with either
v-myc myelocytomatosis viral oncogene homolog (c-Myc) or
KrasG12D. Following intrahepatic injection of the resulting cell
populations, recipient mice rapidly developed tumors with com-
plete penetrance (Fig. 1C).
Surprisingly, the histopathology of tumors triggered by ex-
pression of c-Myc and oncogenic Ras was distinct. Consistent
with previous work (15, 16), tumors induced by c-Myc resembled
human HCC, corroborated by strong nuclear expression of he-
patic nuclear factor 4 alpha (HNF4A) and a granular, cytoplasmic
reactivity with anti-hepatocyte parafﬁn-1 (Hep Par1), an antibody
frequently used in the clinical diagnosis of HCC (Fig. 1E); con-
versely, they were negative for cytokeratin 19 (CK19), a marker
for ductal differentiation. The histological spectrum of resulting
HCCs ranked from pseudoglandular to solid carcinomas (Fig.
S1). In contrast, tumors induced by KrasG12D presented as
a gland-forming adenocarcinoma. As is observed in human ICC,
malignant epithelial cells were surrounded by a marked stromal
desmoplasia that was not observed in tumors overexpressing c-
Myc (Fig. 1 D and E). Although this stromal reaction was trig-
gered by the transplanted cells, it was derived from the host, as
the stromal cells did not stain for the transduced GFP reporter.
These results are consistent with the frequent occurrence of
KRAS mutations in human ICC (6, 8) and their relative in-
frequent occurrence in HCC (22) and indicate that oncogenic
Kras biases the malignant fate of transduced cell populations
to ICC.
Development of an Orthotopic Allograft Model of ICC. The obser-
vations above and previous work suggested that it would be
possible to produce an orthotopic allograft mouse model of ICC
from liver progenitor cells simply incorporating mutant Kras
instead of c-Myc. To achieve this and to eliminate the potential
nonphysiological consequences of Kras overexpression, we intro-
duced a cre-activatable endogenous KrasG12D allele (KraslslG12D)
into our base conﬁguration (23). Next, isolated liver progenitor
cells of the genotype Alb-Cre; KraslslG12D; p53lslR172H/lox (sub-
sequently referred to as AKP cells) were transduced with a GFP
reporter and transplanted intrahepatically into recipient mice. The
recipient animals succumbed to liver cancers with a median sur-
vival of 84 d, signiﬁcantly longer than mice transplanted with AP
cells overexpressing KrasG12D (Fig. 1C, P = 0.045). In contrast,
mice receiving AP cells transduced with a control plasmid did not
develop liver tumors within 9 mo of follow-up. Thus, consistent
with observations from strictly germ-line systems (14), endogenous
KrasG12D cooperated with p53 mutations in our model.
Beyond large tumors in the liver, moribund animals harbor-
ing KrasG12D/mutant p53 tumors often displayed hemorrhagic
ascites and/or breathing failure due to metastatic disease to the lung
(Fig. S2). Histologically, the GFP-expressing tumor cells were
embedded in a GFP-negative and thus recipient-derived stroma
rich in collagen ﬁbers [Fig. 2A, GFP immunohistochemistry
(IHC) and Masson’s trichrome stain]. Flow cytometry revealed
that when gated on the CD45 negative population, only 17–22%
of all cells were GFP positive, illustrating the abundance of
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Fig. 1. Development of genetically deﬁned, onco-
gene-dependent orthotopic allograft models of
liver cancer. (A) Technical outline. ED14.5 fetal liver
cells from Alb-Cre; p53lslR172H/ﬂox (AP) or Alb-Cre;
KraslslG12D; p53lslR172H/ﬂox (AKP) embryos are enzy-
matically isolated and expanded in culture. After
transduction with MSCV-based retroviruses coen-
coding a ﬂuorescent marker and an oncogene or
shRNAs directed against tumor suppressor genes,
cells were orthotopically transplanted into the livers
of recipient mice. (B) Brightﬁeld and ﬂuorescent
images of orthotopic tumors derived from AP cells
expressing retrovirally introduced and GFP-linked
KrasG12D or c-Myc. (C) Kaplan–Meier survival curves
of recipient animals transplanted with KrasG12D or
c-Myc overexpressing AP cells, AKP cells, or AP cells
transduced with a control retrovirus expressing
turbo RFP. n ≥ 4. (D) AP cells overexpressing KrasG12D
give rise to tumors that histologically resemble
moderately differentiated and CK19 positive chol-
angiocarcinoma. GFP expression identiﬁes cancer
cells that originate from transplanted AP cells within
the recipient-derived GFP negative stroma. (Scale
bars, 25 μm.) (E) c-Myc overexpression in AP cells
leads to HCC formation. Strong nuclear staining for HNF4a indicates that tumor cells retain features of hepatocyte differentiation (Upper, normal liver; Lower,
tumor). CK19 is expressed in normal bile duct cells within the liver (Upper) but not in the tumor cells (Lower). Granular, cytoplasmic staining pattern indicates
positivity for HepPar1. (Scale bars, 25 μm, unless otherwise indicated.)
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stroma within the tumors (Fig. S3). The epithelial tumor cells
stained positive for CK19, a marker of ductal differentiation
(Fig. 2A), and were in part mucin producing [conﬁrmed by
Alcian Blue stain (Fig. 2A)]. Finally, the tumors were negative
for HepPar1 (Fig. 2A), conﬁrming they were not hepatocellular
carcinoma. Overall, the model closely recapitulates histologic
hallmark features of moderately differentiated cholangiocarcinoma
in humans.
To determine whether perturbing an established cancer path-
way might further alter the observed tumor phenotypes, we also
transduced parallel populations with vectors expressing short-
hairpin RNAs (shRNAs) targeting Pten (shPten) or a neutral
control (shRenilla). Of note, the Pten shRNA potently suppresses
target gene expression by RNA interference (24), thereby dereg-
ulating the PI3K pathway and mimicking genetic changes that occur
in ICC and many other cancer types (25). Five weeks posttrans-
plantation, recipient mice that had received Pten-suppressed AKP
cells presented with a signiﬁcantly increased tumor burden
compared with mice transplanted with control transduced cells
(Fig. 2B). Importantly, whereas Pten suppression accelerated
tumor growth compared with a control shRNA, it did not sub-
stantially alter the histology of resulting tumors (Fig. 2C). These
results illustrate the potential of the system to study cancer
drivers while maintaining an accurate histology and, further, how
shRNA technology can be incorporated to study loss-of-function
phenotypes. Of note, experiments to document interactions be-
tween oncogenic Kras, mutant p53, and Pten inactivation using
strictly germ-line strains would have required the intercrossing of
six mutant alleles.
FIG–ROS Is a Potent Driver in Cholangiocarcinogenesis. The above
data provide evidence that our ICCmodel will facilitate the in vivo
validation of candidate driver genes identiﬁed through genomic
studies without the time and cost of producing new transgenic or
knockout strains. To examine a functionally uncharacterized le-
sion in this system, we chose to study the FIG–ROS fusion protein
as a potential cancer driver and therapeutic target in ICC. Murine
stem cell virus (MSCV)-based retroviruses encoding a FIG–ROS
cDNA linked to GFP or a control vector expressing turboRFP
(pMSCV-turboRFP-IRES-GFP) were transduced into fetal AP or
AKP liver cells. The resulting cell populations were orthotopically
transplanted into recipient mice, which were monitored for tumor
onset and pathology. In the presence of KrasG12D and mutant p53,
FIG–ROS markedly accelerated tumor growth relative to control
tRFP-expressing tumors (Fig. 3B), with a median survival of 32
d and 79 d, respectively (Fig. 3C, P < 0.0001). Interestingly, in the
absence of KrasG12D, FIG–ROS was still able to promote tu-
morigenesis, but at a reduced penetrance and longer latency
(Fig. 3C).
Gross pathology of moribund mice identiﬁed large tumors in
the liver and frequent lung metastases. Expression of FIG–ROS
in the resulting tumors was indicated by GFP ﬂuorescence and
further conﬁrmed by ROS1 immunohistochemistry on tumor
sections (Fig. 4A). Histologically, FIG–ROS-expressing tumors
derived from AKP cells presented as cholangiocarcinoma, albeit
with increased areas of poor differentiation (Fig. 4A). Accord-
ingly, CK19 expression remained positive and stromal desmo-
plasia was present. By marked contrast, all three tumors that
arose in the absence of mutant Kras resembled HCC, conﬁrmed
by the presence and absence of HNF4α- and CK19 staining,
respectively. These observations underscore the plasticity of the
fetal liver-cell–based system and the linkage between tumor
histopathology and driving genetic events (Fig. 4D).
ROS triggers the phosphorylation of Shp2 and other effector
proteins and exerts its function through multiple effectors, in-
cluding components of the Jak/Stat, MAPK, and PI3K pathways
(26). Accordingly, tumor cell lines established from FIG–ROS-
expressing tumors showed up-regulation of known ROS1 effec-
tors such as pShp2 and pStat3 by immunoblotting, compared
with control cell lines established from either tRFP- or shPten-
expressing tumors (Fig. 4C). pAkt levels were elevated in both
the FIG–ROS and the shPten cell lines, as expected. These cells
rapidly formed lethal tumors that, at low passage, retained the
histopathology of ICC upon retransplantation into recipient
mice (Fig. 4B). These observations conﬁrm that the primary
ICCs were indeed malignant and establish panels of genetically
characterized tumors that can be used for preclinical studies to
assess candidate ICC therapeutics.
FIG–ROS Is Required for the Maintenance of ICC. Owing to their
deregulated tyrosine kinase activity, ROS1 fusion oncoproteins
represent potential therapeutic targets. Still, all ROS inhibitors
identiﬁed to date target multiple kinases and are insufﬁcient
tools to demonstrate that ROS activity is required for tumor
maintenance. To examine this question in ICC, we used the
tetracycline-based conditional expression system to ask whether
inhibition of FIG–ROS in established cancers would have an
anticancer effect. Adapting the approach shown in Fig. 5A, we
generated a retrovirus that constitutively expresses mCherry to
track transduced cells and the FIG–ROS cDNA linked to a GFP
reporter under the control of a tet-responsive promoter. AKP
cells were cotransduced with the doxycycline-inducible FIG–ROS
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Fig. 2. The AKP hepatoblast transplantation
model gives rise to tumors that resemble primary
human ICC and enables functional validation of
oncogenic drivers. (A) Histopathology of tumors
generated by orthotopic injection of GFP-transduced
AKP cells. H&E reveals gland-forming epithelial
cancer cells that express the ductal differentia-
tion marker CK19. GFP IHC distinguishes between
GFP-positive cancer cells derived from the trans-
planted cells and recipient-derived GFP-negative
desmoplastic stroma rich in collagen ﬁbers (dark
blue in Masson’s trichrome stain). Mucin-producing
cells in well-differentiated areas appear as dark
blue in the Alcian Blue stain. (Scale bars, 25 μm.)
(B) Tumor burden is increased by RNAi-mediated
knockdown of the tumor suppressor Pten. Mice
were injected with AKP cells transduced with
either a control hairpin (shRenilla) or a potent
shRNA targeting Pten (shPten) and eutha-
nized 5 wk after transplantation. Efﬁcient Pten
knockdown is conﬁrmed by immunoblot on
GFP sorted cells from shPten tumors. (C ) AKP cells transduced with shPten lead to CK19 positive, moderately differentiated ICC. (Scale bars, 25 μm.)
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expression construct as well as a retroviral construct encoding
for a reverse tet transactivator (rtTA3) (pMSCV–rtTA3–PGK–
puromycin-resistance), enabling FIG–ROS expression to be re-
versibly induced by addition of the tetracycline analog, doxycycline
(dox). Accordingly, dox-dependent expression of FIG–ROS was
conﬁrmed by immunoblotting (Fig. 5B).
Transduced cells were transplanted s.c. into recipient mice and
the animals were placed on a dox-containing diet to enforce
FIG–ROS expression. Successful engraftment of cells was con-
ﬁrmed by whole body ﬂuorescence detection of the constitutively
active red ﬂuorescent reporter (mCherry) 10 d postinjection.
Two weeks after implantation, all mice (nine of nine) on dox
developed measurable tumors and were randomized into two
treatment arms: ﬁve mice continued on dox, whereas the re-
maining mice were returned to regular mouse chow (off dox).
These experiments decisively established the importance of
FIG–ROS for cancer maintenance. Hence, whereas tumors in
mice maintained on dox grew rapidly, tumors from mice switched
to an off-dox diet remained stable until 5 wk postimplantation
(Fig. 5D). At this stage, masses derived from FIG–ROS-silenced
tumors consisted of mostly cystic lesions harboring only small
solid components that, histologically, were substantially less
cellular than on-dox tumors and were dominated by the stromal
compartment (Fig. 5E, H&E). Of note, a control group of mice
that was continuously kept off dox after transplantation did not
develop measurable tumors until 7 wk postinjection.
The primary cellular response to FIG–ROS withdrawal ap-
peared to be cell-cycle arrest, as observed by the reduced Ki67
staining within the remaining epithelial tumor cells in the dox-
withdrawal cohort compared with on-dox samples (Fig. 5E).
Accordingly, FIG–ROS withdrawal in cultured tumor cells led to
efﬁcient down-regulation of ROS effector pathways accompa-
nied by a reduction in colony formation in vitro (Fig. S4 A–C).
The fact that these advanced ICCs remained “addicted” to FIG–
ROS expression was particularly surprising, given these tumor
cells also harbored Kras and p53 mutations, and implies that
human cholangiocarcinoma patients harboring the FIG–ROS
fusion may greatly beneﬁt from molecularly targeted therapy
aimed at ROS1 fusions.
Discussion
Intrahepatic cholangiocarcinoma is a fatal yet understudied
primary malignancy of the liver. To advance the understanding
of the genetics and biology of this highly aggressive disease, we
generated a genetically tractable mouse model of ICC that is
based on the isolation and in vitro modiﬁcation of fetal liver cells
harboring Kras and p53 mutations, two of the most common
genetic alterations found in human ICC (6–8). We conﬁrmed
that tumors generated in this model closely resemble the histo-
pathology of human ICC and display key characteristics like
CK19 expression of the epithelial tumor cells and abundant
stromal desmoplasia. We believe this is an important feature of
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the model as previous work from pancreas carcinoma—another
glandular carcinoma also driven by KRAS mutations—indicates
the stromal microenvironment has a major impact on cancer
trajectory and treatment response (27).
Although recent advances in sequencing technologies have
enabled in-depth characterization of the genomic landscape of
human cancers, studies on the functional consequences of somatic
mutations in cancer are necessary to understand the mechanistic
impact of individual lesions and to identify candidate therapeutic
approaches for targeting cancers of speciﬁc genotypes. The op-
portunity to genetically modify progenitor cells by retroviral gene
transfer in vitro before transplantation allows for the rapid
functional annotation of cancer genes and thus makes this mouse
model much more ﬂexible than those derived solely from germ-
line alleles.
Beyond analysis of single genes, orthotopic allograft models
enable in vivo pool-based screens for candidate oncogenes and
tumor suppressor genes identiﬁed from genomic studies (28–30),
and it seems likely that this ICC model will be highly amenable to
this approach. Moreover, because genetic alterations are exclu-
sively introduced into the epithelial cells but not in the recipient-
derived stroma, the transplant approach may also serve as
a valuable tool to investigate tumor–stroma interactions, with the
ﬂuorescent marker providing a convenient method to separate tu-
mor and stromal compartments.
The Albumin-Cre used in our model becomes active in pro-
genitor cells capable of differentiating into either the hepatocyte
or bile duct lineage. Activation of KrasG12D using Alb-Cre pro-
duces a ductal adenocarcinoma with all of the features of ICC. In
line with previous reports (15), when these same progenitor-
enriched populations were transduced with c-Myc, the resulting
tumors present as hepatocellular carcinoma. Apparently, Kras
mutations predispose liver progenitor cells to ICC. Although the
molecular basis underlying this observation remains unknown,
the outcome is consistent with the observed incidence of these
lesions in the human setting: increases in MYC copy number
and/or expression are common in HCC, whereas activating
mutations in KRAS are common in ICC. Of note, enforced
expression of oncogenic Hras produces a mixed ICC/HCC model
(31, 32), further underscoring the impact of initiating oncogenic
lesions to impact the histopathology of liver malignancies.
Initially identiﬁed in a glioblastoma cell line (33, 34), trans-
locations leading to the constitutive activation of ROS1 kinase
have been observed in a variety of tumor types. Our results
validate FIG–ROS as a potent oncogene in a mouse model of
cholangiocarcinoma, where it potently cooperates with KrasG12D
and mutant p53 to accelerate tumor onset, leading to an ag-
gressive and metastatic disease. Interestingly, the ability of FIG–
ROS to promote ICC was dependent on the presence of activated
Kras, as FIG–ROS expression in its absence produced hepato-
cellular carcinoma at long latency and incomplete penetrance.
These results are unexpected and suggest that, in ICC, signaling
downstream of ROS1 complements but does not substitute for
KRAS action. That FIG–ROS can drive HCC in the absence of
oncogenic KRAS underscores the importance of KRAS in pro-
ducing ductal carcinomas and suggests a broader but as yet un-
documented role of ROS1 fusions in hepatobiliary malignancies.
Although KRAS and TP53 mutations are among the most
frequent genetic alterations in cholangiocarcinoma and other
cancers, efforts to produce drugs targeting these mutations have
TREtight FIG-ROS IRES GFP EF1s mCherry
rtTA3 PGK PuroR
ROS1
Tubulin
4 weeks on dox
2 weeks after 
dox withdrawal
m
C
he
rr
y
A ctrl
G
FP
B
rig
ht
fie
ld
B
C D
2 
w
ee
ks
 d
ox
 w
ith
dr
aw
al
4 
w
ee
ks
 o
n 
do
x
Ki67 IHC
0
2
4
6
10
20
30
40
continued on dox
dox withdrawal
Time after randomization [days] 
Tu
m
or
 v
ol
um
e 
in
cr
ea
se
H&E GFP IHC
50μm
E
0 2 4 6 8 10 14 17
+
 d
ox
-
 
do
x
Fig. 5. Doxycycline-regulated expression of FIG–
ROS demonstrates its role in tumor progression and
conﬁrms the oncogenic fusion as a potent drug
target. (A) Schematic of the tet-on vector system
used for the reversible expression of FIG–ROS.
TREtight-driven FIG–ROS expression linked to a GFP
ﬂuorescent reporter allows for the inducible, re-
versible expression of the oncogenic fusion. mCherry
under a constitutive promoter serves as a marker
of integration. The reverse tet-transactivator ele-
ment (rtTA3) is encoded on a separate vector due to
size limitations. (B) Immunoblot of primary ED14.5
fetal liver cells cotransduced with the inducible
FIG–ROS and the rtTA3 expression construct con-
ﬁrming the expression of ROS1 only in the presence
of doxycycline. Control: untransduced fetal liver
cells. (C) Brightﬁeld and ﬂuorescent images of tumors
derived from AKP cells transduced with the in-
ducible FIG–ROS expression system. Recipient mice
were either kept on dox food for 4 wk or changed
to regular mouse chow 2 wk after injection. Efﬁ-
cient quiescence of GFP ﬂuorescence in the off-dox
tumor indicates termination of FIG–ROS expression.
(D) Mice s.c. injected with primary AKP cells trans-
duced with the inducible FIG–ROS system were
kept on dox food for 14 d and then randomized
to either continue on dox food or return to regular
mouse chow. Tumor volume was followed by cali-
per measurements. FIG–ROS-expressing tumors grew
rapidly, whereas tumor growth was abrogated in
the dox-withdrawal cohort. (E) Representative his-
tological images from on- versus off-dox tumors.
On-dox tumors exhibit abundant actively pro-
liferating cancer cells as assessed by Ki67 staining.
Off-dox tumors are less cellular with more deﬁned
ductal structures and only a few Ki67-positive cells.
GFP IHC: loss of GFP indicates effective termination
of FIG–ROS expression. (Scale bars, 50 μm.)
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proven unsuccessful. Our results imply that ROS1 inhibitors
would be effective against a subset of human ICC harboring
ROS1 fusion proteins. Although these events are relatively rare,
small molecule inhibitors capable of inhibiting ROS1 kinase
activity have been identiﬁed and are in clinical trials in lung
cancer patients harboring tumors with ROS1 fusion events (35).
As more druggable targets are identiﬁed in cholangiocarcinoma
through genomic or genetic approaches, we expect that this
orthotopic allograft mouse model will provide a powerful plat-
form to investigate their impact on the initiation and mainte-
nance of the disease.
Materials and Methods
Generation of Liver Carcinomas. All animal experiments were performed in
accordance with a protocol approved by the Memorial Sloan–Kettering In-
stitutional Animal Care and Use Committee. Isolation, culture, and retroviral
transduction of fetal liver cells have been described previously (15, 16).
Brieﬂy, fetal liver cells were isolated by dispase digestion from developmental
day14.5 mouse embryos, frozen, genotyped, and retrovirally transduced with
MSCV-based vectors before orthotopic implantation. For subcapsular in-
jection, the animals were anesthetized with isoﬂurane, and analgesia was
provided by s.c. administration of buprenorphine directly before surgery. A
subcostal transversal abdominal incision was performed and the left liver lobe
was exposed. A total of 0.5–1 × 106 cells resuspended in 25 μL Matrigel were
injected under the liver capsule using a Hamilton syringe and a 30-gauge
needle. The injection site was sealed with Vetbond tissue adhesive (3M) and
the abdominal wall was sutured using 4-0 Vicryl. The skin was closed with
wound clips.
Doxycycline feed (625 mg/kg) purchased from Harlan Laboratories was
replenished twice weekly. For orthotopic tumors, animals were killed when
tumors reached a diameter of 10–15 mm as assessed by palpation or upon
displaying signs of deterioration such as breathing failure or abdominal
ascites. S.c. tumor volume was assessed by caliper measurements and cal-
culated as 0.5 × length × width2 (length > width).
Derivation of Tumor Cell Lines. Tumors were isolated, mechanically dissociated
with a scalpel, and subsequently enzymatically digested in DMEM supple-
mented with collagenase (2 mg/mL; Sigma C5138) and DNase I (4 units/mL;
Ambion 2222) for 60 min at 37 °C in a shaking incubator (70 rpm). Crude
digests were washed twice with PBS. For FACS, cells were stained with CD45-
APC/Cy7 for 15 min at 4 °C after performing ACK lysis (5 min at room tem-
perature). To generate cell lines, enzymatic digests were plated in DMEM
supplemented with 10% (vol/vol) FBS and penicillin/streptomycin onto gel-
atin-coated cell culture dishes. Cells were enriched for epithelial tumor
cells by differential trypsinization or by FACS sorting for GFP.
Statistical Analysis. Statistical analysis was performed using GraphPad Prism
software by applying the log-rank (Mantel–Cox) test to compare survival
data and the unpaired two-tailed t test for all other experimental data.
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